Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome
About
Immune-mediated, non-communicable diseases, such as autoimmune diseases, allergic diseases and asthma, are chronic disorders in which the immune system plays a pivotal role. The World Health Organisation (WHO) has highlighted the seriousness of autoimmunity and its association with exposure to the environment.
EXIMIOUS aims to deliver a new way of assessing the human exposome, i.e. the exposures to environmental factors that one experiences throughout life, and shed light on its association to immune-mediated diseases.
Network
EXIMIOUS is part of the European Human Exposome Network and brings together 15 partner organisations from 7 European countries.
Latest Tweets
Latest news
Immune differentiation linked to age and exposure: outputs from the 3rd EXIMIOUS Symposium
More than 70 participants joined the second EXIMIOUS Symposium. Did you miss it? Read about it here and watch the full recording.
EHEN’s April 2022 Newsletter – insights into exposure data
The European Human Exposome Network (EHEN) just released its second newsletter, with updates from the network’s working groups and its exposome projects, including EXIMIOUS.
The EXIMIOUS profile paper is published
“The EXIMIOUS project—Mapping exposure-induced immune effects: connecting the exposome and the immunome” has been published online in Environmental Epidemiology.
Project facts
EXIMIOUS is a 5 year Research and Innovation Action funded by the European Union’s Horizon 2020 programme.
- Concept: introduce a new approach to mapping exposure-induced immune effects by combining exposomics and immunomics in a unique toolbox.
- Budget: 10.8 million Euro
- Duration: 01.01.2020 - 31.12.2024
FAQ
Don’t know what the exposome is?
Want to know more about exposure-related immune diseases?
Curious to know more about what to expect from this project?
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874707.
